GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
GT Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.69−0.34 (-4.84%)
Close on Oct 19, 2026
- Market cap
- $259.71M
- P/E (TTM)
- –
- Dividend yield
- –
Price history
Daily open, high, low, close and volume
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Daily prices are not in StockData yet. This table fills in once an end-of-day price source is connected. | ||||||
Stock splits
From SEC filings
| Date | Ratio | Effect on per-share figures |
|---|---|---|
| Sep 8, 2026 | 1-for-25 reverse | Earlier per-share figures multiplied by 25 |
| Mar 26, 2024(first seen in filings) | 1-for-30 reverse | Earlier per-share figures multiplied by 30 |
| Feb 5, 2024 | 1-for-30 reverse | Earlier per-share figures multiplied by 30 |
| Feb 11, 2021 | 1-for-17 reverse | Earlier per-share figures multiplied by 17 |
| Mar 30, 2016(first seen in filings) | 1-for-250 reverse | Earlier per-share figures multiplied by 250 |